Chary, Sowmya
Amrein, Karin
Lasky-Su, Jessica A.
Dobnig, Harald
Christopher, Kenneth B.
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 GM115774)
Article History
Received: 5 August 2020
Accepted: 11 January 2021
First Online: 17 February 2021
Competing interests
: Dr. Chary was a Masters student at Harvard Medical School during the implementation of the study. During her Masters, Dr. Chary was employed at Takeda Pharmaceutical Company and is currently employed by Biogen, Inc. Dr. Chary reports receiving salary and stock options from Takeda and from Biogen. Neither Takeda nor Biogen had any involvement in the VITdAL-ICU trial, the identification of metabolites, the post hoc study design, analysis of metabolomics, interpretation of the data, access to the data or writing of the manuscript. Dr. Lasky-Su served as a consultant and received personal fees from Metabolon, Inc., outside the submitted work. Dr. Amrein reports receiving lecture fees from Fresenius Kabi. Dr. Dobnig reports receiving lecture fees from Fresenius Kabi. Dr. Christopher reports no financial or other relationships that might lead to a conflict of interest.